GlassScriptPhysician profile
Jennifer D Sutton
NPI 1588194963
$9,334.26
in general payments reported to CMS, 2019-2025
27 companies · $906 in 2025
The $906 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,851 · 2022: $2,060 · 2023: $1,335 · 2024: $1,182 · 2025: $906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,269 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,268.93 |
| Education | $154.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,595.22 | 2021-2024 | Proclaim, Eterna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,675.73 | 2021-2025 | Relistor |
| Abbvie INC. | $1,365.39 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $874.89 | 2021 | |
| Hikma Pharmaceuticals USA | $733.68 | 2022-2023 | Kloxxado |
| Valinor Pharma, LLC | $698.42 | 2023-2025 | Movantik |
| Redhill Biopharma INC. | $364.85 | 2021-2023 | Movantik, Aemcolo, Talicia |
| Collegium Pharmaceutical, INC. | $258.52 | 2023-2025 | Belbuca, Xtampza |
| Nalu Medical, INC. | $198.17 | 2021-2025 | Nalu Neurostimulation System |
| Teva Pharmaceuticals USA, INC. | $70.38 | 2021 | |
| Allergan, INC. | $54.08 | 2021 | |
| Scilex Pharmaceuticals INC. | $53.57 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $49.81 | 2022 | |
| Saluda Medical Americas, INC. | $40.02 | 2024 | Evoke |
| Celgene Corporation | $34.70 | 2023 | Zeposia |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alfasigma USA, INC. | $34.34 | 2022 | |
| Painteq LLC | $30.98 | 2023 | Painteq |
| Pfizer INC. | $27.88 | 2024 | |
| Electronic Waveform Lab, INC. | $26.69 | 2021 | |
| Indivior INC. | $23.31 | 2025 | Sublocade |
| Spr Therapeutics, INC | $22.97 | 2022 | |
| Zoll Respicardia, INC. | $22.08 | 2023 | Remede System |
| Tonix Medicines, INC. | $20.52 | 2025 | Tonmya |
| Novartis Pharmaceuticals Corporation | $17.80 | 2021 | |
| Nevro Corp. | $14.70 | 2021 | |
| Boston Scientific Corporation | $12.97 | 2021 | |
| Almatica Pharma LLC | $12.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Sutton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.